无活性构造结合EGFR抑制剂的结构-活性关系:将ATP和囊结合起来
Surbhi P Chitnis1, Florian Wittlinger2,3, Mareike Möllers2
1Department of Chemistry, The State University of New York at Buffalo, Buffalo, New York, USA.
针对非小细胞肺癌 (NSCLC) 的下一代EGFR抑制剂是通过探索ATP位 imidazole支架来开发的. 新的背口袋结合组显示出高强度,为酶抑制剂的发现提供了新的方向.
科学领域:
- 药用化学 医学化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 表皮生长因子受体 (EGFR) 氨酸激酶是非小细胞肺癌 (NSCLC) 的关键标.
- 耐药性突变的出现需要开发下一代EGFR抑制剂.
- 以前的研究忽略了针对EGFR背囊的ATP竞争性抑制剂.
研究的目的:
- 研究将功能组纳入ATP站点的伊米达醇支架中,用于EGFR氨酸激酶抑制剂 (TKI).
- 确定新的结合策略,以克服EGFR阳性NSCLC中的抗性突变.
主要方法:
- 对扩展到EGFR后口袋的功能组进行系统调查.
- 使用多种替代剂设计和合成基于伊米达的支架.
- 对抑制剂强度的评估和结合相互作用的结构分析.
主要成果:
- 用和/或基组在后口袋基中代谢替代的胺链接剂表现出最高的功效.
- 功能组与EGFR背囊之间的特定结合相互作用的识别.
- 通过新型的伊米达支架来准EGFR背口袋的可行性已被证明.
结论:
- 基于伊米达的新型支架,具有特定的后口袋相互作用,是下一代EGFR技术知识产权的一个有希望的战略.
- 这些发现为发现和优化酶抑制剂的新方向提供了新的方向,这些抑制剂针对非活性构造.
- 开发的抑制剂显示出克服EGFR突变NSCLC中耐药性的潜力.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
08:09Mapping the Binding Site of an Aptamer on ATP Using MicroScale Thermophoresis
Published on: January 7, 2017
相关概念视频
Ligand Binding and Linkage
Allosteric Regulation
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Receptor Tyrosine Kinases
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
